Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

EBV Lymphomas Clinical Trial

Official title: A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies

Status Terminated

Clinical Trial Summary

The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• EBV Lymphomas
• Lympho-proliferative Diseases
• Lymphoproliferative Disorders

• NCT number: NCT00917826
• Study type: Interventional
• Source: HemaQuest Pharmaceuticals Inc.
• Status: Terminated
• Phase: Phase 2
• Start date: September 2008